March 9, 2011 -- WuXi PharmaTech, a dominant player in China’s CRO/CMO space, today announced a solid 24% growth in revenues during 2010, and the company guided investors to expect a further 20% increase in its top-line for 2011. During 2010, WuXi’s sales totaled $334.1 million. The company predicts they’ll reach around $400 million in 2011, a steady progression from an enterprise that, at the moment, is not providing surprises. More details....
Stock Symbol: (NYSE: WX)
